First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial-Reference-Cited by-同舟云学术

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Published:2023-10 Issue:10 Volume:24 Page:1073-1082
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cytryn Samuel L,Moy Ryan H,Cowzer Darren,Shah Ronak H,Chou Joanne F,Joshi Smita S,Ku Geoffrey Y,Maron Steven B,Desai Avni,Yang Jessica,Sugarman Ryan,Rao Devika,Goldberg Zoe,Charalambous Carmelina,Lapshina Maria,Antoine Ariel,Socolow Fiona,Trivedi Nikhil,Capanu Marinela,Gerdes Hans,Schattner Mark A,Simmons Marc,Lacouture Mario E,Paroder Viktoriya,Tang Laura H,Shia Jinru,Ilson David H,Solit David B,Berger Michael F,Janjigian Yelena Y

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study;Sun;Lancet,2021

3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021

4. Janjigian YY, Shitara K, Moehler MH, et al. Nivolumab plus chemotherapy vs chemo as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow up from CheckMate 649. 2023 Gastrointestinal Cancers Symposium; Jan 19–21, 2023; San Francisco, CA, USA (abstr LBA291).

5. Resistance mechanisms to anti-PD cancer immunotherapy;Vesely;Annu Rev Immunol,2022

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

2. The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma;Expert Opinion on Biological Therapy;2024-08-28

3. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma;Nature Communications;2024-08-09

4. Interleukin-6 serves as a critical factor in various cancer progression and therapy;Medical Oncology;2024-06-20

5. Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer;International Journal of Clinical Oncology;2024-05-11